Clinical trial

A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152) in Combination…

NCT00000803 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00000803
Title A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
Official title A Phase II Double-Blind Study of Delavirdine Mesylate ( U-90152 ) in Combination With Zidovudine ( AZT ) and/or Didanosine ( ddI ) Versus AZT and ddI Combination Therapy
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Status Completed
Phase Phase 2
Study type Interventional
Conditions HIV Infections
Intervention type Drug
Interventions Delavirdine mesylate, Zidovudine, Didanosine
Enrollment 471
Completion Mar 1, 1997
First posted Aug 31, 2001
Last update posted Nov 4, 2021
Countries Puerto Rico, United States

At a glance

  • 10–99 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies